



Press release

Transaction with Philips approved by SHL shareholders

Tel Aviv/Zurich, 28 November 2007 – SHL Telemedicine Ltd. (SWX: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, announces that in a Special General Meeting convened in Tel Aviv yesterday, with 42% of all shareholders being present, all proposed resolutions with regard to the transaction with Royal Philips Electronics for the sale of SHL's US Raytel Cardiac Services and other ancillary operations were approved and authorized.

SHL is to receive around USD 110 million as upfront cash consideration and debt assumption. In addition, SHL will participate on a revenue sharing and royalty basis for up to 9 years in revenues of Raytel's current services and certain future services to be introduced in North America for which certain minimum payments will be made pending achievement of agreed upon milestones. SHL will also benefit from the sales of its proprietary telemedicine devices to Philips as well as from revenues emanating from Philips' access to SHL's future R&D. On consummation of the transaction SHL will record a significant capital gain, and going forward SHL anticipates its operations will generate a net profit together with significantly improved margins and cash position.

The closing of the transaction with Philips is scheduled for 30 November 2007.

About SHL TeleMedicine

SHL TeleMedicine Ltd. is a leading provider and developer of advanced personal telemedicine solutions to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in the US, Europe and Israel. SHL is listed on the SWX Swiss Exchange, symbol SHLTN. For more information please visit our web site on www.shl-telemedicine.com.

IR Agenda 2008:

26 March	FY results 2007
14 May	Annual General Meeting
20 May	Q1 results
26 August	Q2 results
18 November	Q3 results

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Assistant: Pauline Shavit, Phone: +972 3561 22 12, pauline@shl-telemedicine.com
- Martin Meier-Pfister, The Investor Relations Firm AG, Phone: +41 43 244 81 40, shl@irfirm.biz



Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.